The Evaluation of Venous Thromboembolism/Adverse Drug Events in VA Loma Linda Oncology Patients on Warfarin vs Low Molecular Weight HeparinSeptember 23, 2015Oncology
Did the FDA Black Box Warning Have Any Effect on Erythropoiesis-Stimulating Agent Use?September 23, 2015Oncology
Comparison of Initial Diagnosis and Treatment for Hepatocellular Carcinoma Between VA and Nonveteran PopulationsSeptember 23, 2015Oncology
A Retrospective Evaluation of Outcomes in Veteran Patients With Agent Orange Exposure and Prostate CancerSeptember 23, 2015Oncology
The Efficacy of Abiraterone Pre-and Postdocetaxel and Sequential Use of Enzalutamide After Abiraterone in Veteran Patients With Metastatic Castration-Resistant Prostate CarcinomaSeptember 23, 2015Oncology
Improving the Accuracy of Ordering and Reporting for Send-Out Laboratory StudiesSeptember 23, 2015Oncology
PSA Response Rates Far Exceeded Expectations in Treating Asymptomatic, Androgen-Resistant Prostate Cancer With AbirateroneSeptember 22, 2015Oncology
Prevalence of Prostate-Specific Antigen Testing Informed Consent Among Veteran Males Aged 55 to 69 YearsSeptember 22, 2015Oncology
Veterans With Castration-Resistant Prostate Cancer: Characteristics and TreatmentSeptember 22, 2015Oncology
Audiologic Rehabilitative Service Utilization Among Veterans Exposed to Cisplatin: A Retrospective ReviewSeptember 22, 2015Oncology
A Veterans Health Administration Disease Management Program: The Hudson Valley ModelSeptember 21, 2015Oncology
